Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC

Recruiting Phase 2 Interventional Study
NSCLC (Non-small Cell Lung Cancer)
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 75
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
38 (estimated)
Sponsor
Tianjin Medical University Cancer Institute and Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This is a Phase II single-arm study designed to evaluate the efficacy and safety of cryoablation combined with tislelizumab and platinum-based doublet chemotherapy as neoadjuvant therapy, followed by adjuvant tislelizumab therapy in patients with resectable stage II-IIIB non-small cell lung cancer (NSCLC). The study consists of a screening phase, a treatment phase (including the neoadjuvant stage…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Aged ≥18 years at informed consent signing. * ECOG performance status of 0 or 1. * Histologically confirmed stage II-IIIB NSCLC (AJCC 9th edition). * Tumor size ≤5 cm. * Deemed suitable for R0 resection by a thoracic surgeon for radical treatment. * Adequate cardiopulmonary fu…
Contacts

Donsheng Yue Chief Physician of Surgery

+8602223109106

yuedongsheng_cg@163.com

CONTACT